Ocuphire Pharma Results Presentation Deck
RM
26
●
●
●
●
Summary of RM Market Opportunity
A Substantial Revenue Opportunity for Nyxol in Reversal of Mydriasis
~100M comprehensive and specialty eye exams in US per year
No current commercially available treatment for reversing dilation
Optomap ultra-wide field camera used for a retinal evaluation without the need for dilation;
-$40-$65 cost to patient¹
Findings from recent US market research²:
Over 65% patients report moderate to severe negative impact of dilated exams
Cash pay price range surveyed $5-$20 per patient treatment
45% patients said they would likely request a dilation reversal drop
Estimated US Market Opportunity- $325M- $1B+
-
-
Eye exam market posted a 3.3% growth to $6.39B³
Given the efficacy of Nyxol to reverse dilation regardless of eye color, there are
additional markets outside of the US for potential commercialization
1. Corcoran Consulting Group FAQ for Optomap imaging 01/2021
2. GlobalData market research report
3. Vision Care Market Grows 2.4 Percent in 12-Months Ending September 2019. Vision Monday, January 20, 2020.
Ocuphire
PHARMAView entire presentation